Natera Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 52.89 M44.45 M37.57 M59.39 M73.89 M 215.3 M Mittelzufluss aus Investitionstätigkeit -11.12 M-16.82 M-23.9 M-19.91 M-71.59 M -132.21 M Zahlungsströme aus der Finanzierungstätigkeit 10.97 M544 K12.58 M1.94 M32.41 M 47.46 M Freier Cashflow 34.77 M22.64 M11.68 M36.98 M37.82 M 109.11 M

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas.

NTRA

Financials

Natera Inc

Nachrichten

Piper Sandler bestätigt GeneDx mit "Overweight" und Kursziel 130 $

Tracking Philippe Laffont's ~$40B Coatue Management Portfolio—Q4 2025 Update

Cathie Woods ARK stößt Roku-Aktien ab und investiert in Tempus AI

Monday’s insider activity: Vail Resorts CEO buys $4.9 million

NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases

Natera ctDNA test shows promise in anal, rectal cancer studies

GeneDx-Aktie unter Druck: Natera bringt konkurrierenden Gentest auf den Markt

GeneDx stock falls as Natera launches competing rare disease test

Natera launches whole genome sequencing test for rare diseases

Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio – Q4 2025 Update

Natera at Leerink Global Healthcare Conference: Strategic Growth and Investment